Ardmac, a leader in construction services, joined West Pharmaceutical Services and government leaders to announce the opening of the new medical device facility in Damastown, Co Dublin.
Ardmac is delighted with the completion of the Medical Device Design & Build Project for West Pharmaceutical Services, providing the handover four weeks early. The 60,000ft2 building includes new cleanrooms, production, warehousing, office support and canteen along with associated site facilities near Damastown, County Dublin.
The expansion is in response to customer demand for medical device manufacturing—especially in the area of diabetes—and represents West's most recent investment in Ireland.
The additional capacity in Dublin will make it possible to better service the Company's growing healthcare and medical device contract manufacturing business. West anticipates 100 new jobs will be added to the business over the next five years as a result of the expansion.
'As the healthcare market becomes increasingly complex, West is advancing our core competencies in the development, manufacturing and final packaging of complex drug delivery systems and diagnostic devices for our customers,' said Karen Flynn, Senior Vice President and Chief Commercial Officer, West.
'We are excited about the growth and expansion we are experiencing in both our contract manufacturing business in Dublin as well as our proprietary products business in Waterford, both of which will support increasing demand from our global customer base.'
West anticipates 100 new jobs will be added to the business over the next five years as a result of the expansion.
According to Alan Coakley, Managing Director of Ardmac: 'We are delighted to be celebrating another successful completion on behalf of West Pharmaceutical Services. Being a global leader in cleanroom construction for the pharmaceutical and life sciences sector, coupled with our construction capability, Ardmac were uniquely suited to design and build this medical device manufacturing facility.
This facility is testament to the excellent reputation of West Pharmaceutical Service as leaders in integrated packaging and delivery for injectable medicines. We are very proud to have been selected; delivering the project safely, early and on budget. We look forward to continuing our great partnership with West Pharmaceutical Services in the future.'
The green-field project included the design of all Structural, Civil, Architectural, Mechanical and Electrical elements, which included;
- Use of 3d Revit modelling throughout the design and construction phases of the project
- Fit-out of new office, canteen, and toilet areas Construction of warehouse & plant areas
- Construction of cleanrooms
- Mechanical, electrical, sprinkler and process installations
- External works including roads, carparking, loading docks, drainage and attenuation tanks.
'We are very pleased with West's commitment to furthering operations in Ireland,' said Mary Mitchell O'Connor TD, Ireland's Minister for Jobs, Enterprise & Innovation.
'With this most recent expansion in Dublin and the company's previously announced investment in Waterford, West is affirming its presence as an important employer in Ireland. I am delighted with this new investment, which strongly aligns with the Government's ongoing strategy to attract investment in high-quality, high-value, medical device manufacturing to Ireland. We look forward to strengthening our relationship with West.'
Martin Shanahan, CEO, IDA Ireland said: 'IDA's life science sector continues to grow from strength-to-strength and this investment by West is a good example of the potential for convergence across the life sciences sector. Ireland has seen hundreds of millions invested in recent years in the development and manufacturing of new injectable drugs for diabetes, cardiovascular disease, autoimmune disease and cancer. The patients who will benefit from these exciting new drugs will also benefit from West's innovation in drug delivery devices. IDA welcomes this investment and looks forward to continuing to work with West and their partner biotech companies in further developing the Irish cluster.'
